This figure' shows that the decay "chain" starts with an a decay of 2Ac to produce "Fr, which itself undergoes a decay to "X1", and so on, until the final production of the stable "Bi isotope via a beta- decay process from "XS". Note that isotope "X2" has two different decay channels, both of which result in "XS": 98% of "X2" undergoes B decay to "X3" (which subsequently decays by emitting a to produce XS"), while 2% of X2" decays to "X4" via a decay (which subsequently undergoes B* decay to "X5"). 1. Given the type of decay process, provide the element and nucleon number (e.g. 2"Fr) for each of the isotopes X1, X2, X3, X4 and XS. 2. Assume a chemist in Dr. Ramogida's lab requires 8 hours from the time of receipt of 2Ac to incorporate it into a chemically synthesized carrier compound that can be used for cancer treatment. If they are given 0.450 mg of 2Ac, what is the mass of *Ac remaining at the end of the 8 hours, given its half-life of 9.9 days? 3. If their compound is shipped around the world for treatment of cancer patients, a key consideration is how long it remains active. Starting with the amount that leaves Dr. Ramogida's lab, for how long does at least 10% of the *Ac remain, which could be used for treatment? 4. The half-life of 21Fr is considerably shorter than "Ac: 4.8 minutes. Would you recommend to Dr. Ramogida's team to try to synthesize molecules that can target Francium to tumours, rather than using Actinium? Explain your reasoning. Figure adapted from "Development of Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences", by Robertson, Ramogida, Schaffer and Radchenko. Current Radiopharmaceuticals 11, 156 (2018)

#Q.2: Given the half-life of Ac225, t1/2 = 9.9 days Initial mass of Ac225 taken, No = 0.450 mg

Answered: This figure' shows that the decay "chain" starts with an a decay of 2Ac to produce "Fr, which itself undergoes a decay to "X1", and so on, until the final…

Chemistry

10th Edition

ISBN: 9781305957404

Author: Steven S. Zumdahl, Susan A. Zumdahl, Donald J. DeCoste

Publisher: Cengage Learning

See similar textbooks

Concept explainers

Writing and Balancing Nuclear Equations

A nuclear equation is a symbolic representation of a nuclear reaction using certain symbols. It is studied in nuclear chemistry and nuclear physics.

Question

question 2 please

|225 дс|
9.9 d
a
221Fr
d = days
h = hours
4.8 m
m = minutes
s = seconds
a
ms = milliseconds
us = microseconds
X1
32 ms
a
X2
X3
98% B"
45.6 m
4.2 us
2% a
|209Bİ
B-
X4
X5
2.2 m
3.3 h
stable
This figure' shows that the decay "chain" starts with an a decay of 225Ac to produce 221Fr, which itself
undergoes a decay to "X1", and so on, until the final production of the stable 20°B¡ isotope via a beta-
decay process from "X5". Note that isotope "X2" has two different decay channels, both of which result
in "X5": 98% of “X2" undergoes B decay to "X3" (which subsequently decays by emitting a to produce
"X5"), while 2% of "X2" decays to "X4" via a decay (which subsequently undergoes B" decay to "X5").
1.
Given the type of decay process, provide the element and nucleon number (e.g. 22"Fr) for each of
the isotopes X1, X2, X3, X4 and X5.
Assume a chemist in Dr. Ramogida's lab requires 8 hours from the time of receipt of
225
2.
Ac to
incorporate it into a chemically synthesized carrier compound that can be used for cancer
treatment. If they are given 0.450 mg of 225 Ac, what is the mass of 225
Ac remaining at the end of the
8 hours, given its half-life of 9.9 days?
3.
If their compound is shipped around the world for treatment of cancer patients, a key
consideration is how long it remains active. Starting with the amount that leaves Dr. Ramogida's
lab, for how long does at least 10% of the 225Ac remain, which could be used for treatment?
The half-life of 221Fr is considerably shorter than 225AC: 4.8 minutes. Would you recommend to Dr.
Ramogida's team to try to synthesize molecules that can target Francium to tumours, rather than
using Actinium? Explain your reasoning.
4.
"Figure adapted from "Development of 225AC Radiopharmaceuticals: TRIUMF Perspectives and Experiences", by
Robertson, Ramogida, Schaffer and Radchenko. Current Radiopharmaceuticals 11, 156 (2018)

Expert Solution

This question has been solved!

Explore an expertly crafted, step-by-step solution for a thorough understanding of key concepts.

See solution Check out a sample Q&A here

Step 1

VIEW

Step 2

VIEW

Step 3

VIEW

Step by stepSolved in 3 steps

See solution

Check out a sample Q&A here

Knowledge Booster

Learn more about

Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, chemistry and related others by exploring similar questions and additional content below.

Related questions

Concept explainers